Eric Lefkofsky and the Tempus Approach

Eric Lefkofsky is an American entrepreneur who has made a career out of pooling data in order to help customers and clients reach the goals that they need. Lefkofsky cemented his legacy as a tech guru with his work co-founding the successful company, Groupon. Now, Lefkofsky is turning his attention toward something far more serious than your next meal: cancer research.

Eric Lefkofsky moved on from Groupon to put his full time attention into his next start up, Tempus. Tempus is a company that will fundamentally change the way patients and medical professionals interface with life saving information. No longer will patients have to be told, “We don’t know.” regarding the statistics of medical options that are available to them. Of course, Tempus won’t be a cure-all for anything but the data aggregate process, but it will be hyper important in that regard.

What Tempus will attempt to do, Lefkofsky explains, is change the way we interface with electronic medical records (EMR). EMRs are clunky and hard to access right now. With Tempus they will be funneled into an aggregated system where users on both ends of the spectrum, patient and professional, can access the information that they need. The goal is to give medical professionals more options when trying to assess the ever elusive threat that is cancer while simultaneously giving patients and family members the chance to be more informed when they leave the hospital. This will all be done by a custom made operating system developed by Lefkofsky and the rest of the team at Tempus and what Eric knows.

Eric Lefkofsky is one of the most innovative tech figures in the industry right now and he is putting that sway to use far beyond the commercial realm of entertainment, luxury, and lifestyle. Based out of Chicago, Eric Lefkofsky has already put millions of dollars into cancer research. His work with Tempus will seek to push us toward a world where cancer research actually leads to cancer results. The early focus for Tempus will be toward cancer of the breast, lung, and pancreas with expectations of more cancers being added in the future and read full article.

More Visit: